Abstract
Non-denaturing pressures of around 2000 bar are effective for eliminating and refolding protein aggregates and may be applicable in various phases of protein manufacturing to decrease aggregate levels in products and improve process yields. Lower aggregate levels can result in reduced immunogenicity of proteins and enable the correct refolding of proteins that might not be recovered with traditional techniques. High pressure treatment can also be used to conduct selective PEGylation and protease cleavage reactions while minimizing protein aggregation. High pressure processes have been used in the food industry for over 50 years and large scale (300 L) systems are commercially available, enabling production of proteins on the kilogram scale. This review summarizes the utility of high pressure refolding to remove and refold protein aggregates, enhance therapeutic proteins, and facilitate manufacturing improvements at industrial scales.
Current Pharmaceutical Biotechnology
Title: Application of High Hydrostatic Pressure to Dissociate Aggregates and Refold Proteins
Volume: 10 Issue: 4
Author(s): Matthew B. Seefeldt, Mary S. Rosendahl, Jeffrey L. Cleland and Lyndal K. Hesterberg
Affiliation:
Abstract: Non-denaturing pressures of around 2000 bar are effective for eliminating and refolding protein aggregates and may be applicable in various phases of protein manufacturing to decrease aggregate levels in products and improve process yields. Lower aggregate levels can result in reduced immunogenicity of proteins and enable the correct refolding of proteins that might not be recovered with traditional techniques. High pressure treatment can also be used to conduct selective PEGylation and protease cleavage reactions while minimizing protein aggregation. High pressure processes have been used in the food industry for over 50 years and large scale (300 L) systems are commercially available, enabling production of proteins on the kilogram scale. This review summarizes the utility of high pressure refolding to remove and refold protein aggregates, enhance therapeutic proteins, and facilitate manufacturing improvements at industrial scales.
Export Options
About this article
Cite this article as:
Seefeldt B. Matthew, Rosendahl S. Mary, Cleland L. Jeffrey and Hesterberg K. Lyndal, Application of High Hydrostatic Pressure to Dissociate Aggregates and Refold Proteins, Current Pharmaceutical Biotechnology 2009; 10 (4) . https://dx.doi.org/10.2174/138920109788488914
DOI https://dx.doi.org/10.2174/138920109788488914 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nutritional and Pharmacological Management of Childhood Epilepsy: Ketogenic Diets and Common AEDs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Tocotrienols Stimulate Insulin Secretion of Rat Pancreatic Isolated Islets in a Dynamic Culture
Current Pharmaceutical Biotechnology Metal Complexation Mechanisms of Polyphenols Associated to Alzheimer’s Disease
Current Medicinal Chemistry Dysfunction of Glutamate Receptors in Microglia May Cause Neurodegeneration
Current Alzheimer Research Anti-VEGF Therapy for Retinal Vein Occlusions
Current Drug Targets Cellular and Molecular Mechanisms of Apoptosis in Age-Related Muscle Atrophy
Current Aging Science Tumour Reactions to Hypoxia
Current Molecular Medicine Biologic Therapy in Psoriasis: Safety Profile
Current Drug Safety Editorial (Thematic Issue: Novel Inflammatory Biomarkers in Cardiovascular Disease: From Molecular Mechanisms to Therapeutic Targets (Part-II))
Current Medicinal Chemistry Editorial [Hot Topic: The Era of -Omics (Guest Editor: David M. Pereira)]
Current Pharmaceutical Biotechnology Functional Relevance of Biased Signaling at the Angiotensin II Type 1 Receptor
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacogenomics of Open-Angle Glaucoma
Current Pharmacogenomics and Personalized Medicine Reciprocity in Microbiome and Immune System Interactions and its Implications in Disease and Health
Inflammation & Allergy - Drug Targets (Discontinued) Efficacy and Safety of Corticosteroids’ Administration for Pulmonary Immaturity in Anticipated Preterm Delivery
Current Pharmaceutical Design Regenerative Approaches to Post-Myocardial Infarction Heart Failure
Current Pharmaceutical Design Beyond the HapMap Genotypic Data: Prospects of Deep Resequencing Projects
Current Bioinformatics Glucagon and Glucagon-like Peptide-1 Receptors: Promising Therapeutic Targets for an Effective Management of Diabetes Mellitus
Current Pharmaceutical Design Resorcinol Derivatives as Novel Aldose Reductase Inhibitors: <i>In Silico</i> and <i>In Vitro</i> Evaluation
Letters in Drug Design & Discovery Communication from Tubular Epithelial Cells to Podocytes through Sirt1 and Nicotinic Acid Metabolism
Current Hypertension Reviews Wogonin Alleviates Hyperglycemia Through Increased Glucose Entry into Cells Via AKT/GLUT4 Pathway
Current Pharmaceutical Design